Novaccess Global INC
Market Movers (8-K)
OTC.Pink
NovAccess Global Inc. has entered into a securities purchase agreement for a $65,000 loan, issuing a promissory note and warrants to AJB Capital Investments, LLC, to fund debt repayment, operations, and the filing of its June 30, 2024, quarterly report.
Worse than expected
Capital raise
OTC.Pink
NovAccess Global Inc. reports the resignation of its CFO, Neil J. Laird, effective July 26, 2024, and the appointment of CEO Dwain K. Irvin as interim CFO.
OTC.Pink
NovAccess Global Inc. has entered into an interest-free convertible loan agreement with its chairman, John A. Cassarini, for $9,000 to address short-term cash needs.
Worse than expected
Capital raise
OTC.Pink
NovAccess Global Inc. has entered into a securities purchase agreement for a $117,000 loan and acquired an 18.6% stake in Fendix Media Limited, a UK healthcare marketing firm.
Worse than expected
Capital raise
OTC.Pink
NovAccess Global Inc. has entered into a securities purchase agreement for a $26,500 loan and acquired a new intellectual property license to enhance its immunotherapy platform.
Worse than expected
Capital raise
OTC.Pink
NovAccess Global Inc. has entered into a securities purchase agreement for a $100,000 loan to support its working capital needs.
Worse than expected
Capital raise
Quarterly Earnings (10-Q)
OTC.Pink
NovAccess Global Inc. reports a decreased net loss for the nine months ended June 30, 2024, despite ongoing concerns about liquidity and capital resources.
Worse than expected
Delay expected
Capital raise
OTC.Pink
NovAccess Global reports a net income for the six months ended March 31, 2024, driven by gains on derivative liability and reduced expenses, but faces ongoing liquidity challenges and dependence on additional funding.
Worse than expected
Delay expected
Capital raise
OTC.Pink
10-Q: NovAccess Global Reports Net Income of $1.3 Million for Q1 2024 Amidst Debt and Financing Challenges
NovAccess Global reports a net income of $1.3 million for the quarter ended December 31, 2023, a significant turnaround from the previous year's loss, but faces ongoing liquidity and debt challenges.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OTC.Pink
NovAccess Global Inc., a biopharmaceutical company, reported a significant net loss and a growing working capital deficit for fiscal year 2024, highlighting severe liquidity challenges despite progress in immunotherapy development.
Delay expected
Worse than expected
Capital raise
OTC.Pink
NovAccess Global has filed an amendment to its annual report to correct a minor error in its internal control over financial reporting disclosure.
OTC.Pink
NovAccess Global Inc.'s 10-K filing details its focus on developing novel immunotherapies for brain tumors, its financial challenges, and a recent significant funding agreement.
Worse than expected
Delay expected
Capital raise
Insider Trading (Form 4)
OTC.Pink
Director John Cassarini reports acquiring a $9,000 convertible loan in NovAccess Global Inc. on May 31, 2024, convertible to common stock at $0.11 per share.